BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32903865)

  • 21. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.
    Ambady P; Doolittle ND; Fox CP
    Ann Lymphoma; 2021 Sep; 5():23. PubMed ID: 35253010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis.
    Seidel S; Kowalski T; Nilius-Eliliwi V; Schroers R; Schlegel U
    Neurol Res Pract; 2023 Feb; 5(1):8. PubMed ID: 36814351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
    Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
    Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary central nervous system lymphoma.
    Schaff LR; Grommes C
    Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances and challenges in the treatment of primary central nervous system lymphoma.
    Yang H; Xun Y; Yang A; Liu F; You H
    J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review.
    Tsang M; Rubenstein JL; Pulczynski EJ
    Ann Lymphoma; 2021 Sep; 5():. PubMed ID: 35106521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients.
    Garcilazo-Reyes Y; Alentorn A; Duran-Pena A; Hoang-Xuan K; Houillier C
    Curr Treat Options Neurol; 2019 Jul; 21(8):39. PubMed ID: 31324993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance.
    Wang L; Fan Y; Chen B; Zhang J; Yang L; Qiu X; Jiang H; Li J; Xiao X; Huang L; Xu Y
    Front Oncol; 2023; 13():1333761. PubMed ID: 38348121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
    Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
    J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
    Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
    J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
    Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
    Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
    Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
    Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary central nervous system lymphoma.
    Löw S; Han CH; Batchelor TT
    Ther Adv Neurol Disord; 2018; 11():1756286418793562. PubMed ID: 30305848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How we treat primary central nervous system lymphoma.
    Calimeri T; Steffanoni S; Gagliardi F; Chiara A; Ferreri AJM
    ESMO Open; 2021 Aug; 6(4):100213. PubMed ID: 34271311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.
    Li Q; Ma Y; Lin Z; Ma J; Kang H; Zhang M; Xu H; Chen B
    J Neurooncol; 2023 May; 163(1):39-46. PubMed ID: 35733032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
    Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
    Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.